das COViMS-Register liefert Hinweise darauf, dass Gehbehinderung, höheres Alter und schwarze Hautfarbe mit einem schlechteren klinischen Verlauf von COVID-19 in einer nordamerikanischen MS-Population verbunden sind. https://t.co/m8H7sawv5C
RT @drbarrysinger: @AaronBosterMD #COVID19 risks for people living with #MS on treatment is a concern. Some data suggests B-cell depleting…
@AaronBosterMD #COVID19 risks for people living with #MS on treatment is a concern. Some data suggests B-cell depleting therapy may pose a higher risk of severe COVID-19 while interferon therapy may be safer. https://t.co/L2F9V3RNbi https://t.co/c1RNjAO…
Older age and ambulatory disability, in addition to other risk factors, were associated with poor outcome in patients with #multiplesclerosis and #COVID19 in the COViMS Registry https://t.co/BgZB6ndfgY #MSCOVID19